Latest Conference Articles

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained what patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib reported in regard to their quality of life during treatment.

Bemarituzumab is an investigational, potential first-in-class targeted antibody designed to block specific fibroblast growth factors from binding and activating FGFR2b.

Research has also shown activity with sacituzumab govitecan in subsets of patients with triple-negative breast cancer, such as those with active brain metastases.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the efficacy and safety of lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

In PD-L1-positive patients, tislelizumab improved median overall survival by 3.5 months with a 46% decrease in the risk of death compared with chemotherapy.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, gives an overview of the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, detailed some of the AEs experienced by patients with aRCC who were given either nivolumab plus cabozantinib or sunitinib.

Results from the phase 3 TITAN study shows a combination therapy that includes apalutamide may achieve survival benefit without significant burden of adverse effects.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained how the phase 3 CheckMate 9ER trial was conducted in order to assess the outcomes by baseline disease characteristics for patients with aRCC.

Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, discusses her presentation on nivolumab plus cabozantinib versus sunitinib for aRCC.

Frequent prostate-specific antigen screenings may lower the risk of metastasis at the time of diagnosis and lower mortality risk from prostate cancer among younger African American men.

Rates of death among patients with breast cancer due to any cause were 31% higher in states with Medicaid income eligibility limits no greater than 50% of the federal poverty level.

This is the first and only oncology immunotherapy to show positive phase 3 results in the adjuvant lung cancer setting.

Other HPV-associated cancers were found to have increased over the study period, linking this trend to lack of guidelines and other resources.

Guillermo Rodriguez Navarrete, the founder and CEO of Nutrillermo, and Elaine Ladd, the chief pharmacy officer of Pharmacy Development Services (PDS), discuss the value of the pharmacist in the health and wellness space for patients.

Pharmacy Times spoke with Lauren Simko, managing performance specialist at Pharmacy Development Services, about the future of lengthening the patient lifecycle and further developing pharmacy services.

Pharmacy Times spoke with Lauren Simko, managing performance specialist at Pharmacy Development Services, about how an improved patient experience goes hand-in-hand with lifecycle.

Pharmacy Times spoke with Lauren Simko, managing performance specialist at Pharmacy Development Services, about how elevating the patient experience can increase revenue for pharmacists in the healthcare space.

Guillermo Rodriguez Navarrete, the founder and CEO of Nutrillermo, and Elaine Ladd, the chief pharmacy officer of Pharmacy Development Services (PDS), discuss the role of social media in the health and wellness space.

Guillermo Rodriguez Navarrete, the founder and CEO of Nutrillermo, and Elaine Ladd, the chief pharmacy officer of Pharmacy Development Services (PDS), discuss whether the shift in the public's awareness of the critical role of the pharmacist during the pandemic could support pharmacists’ move to a more significant role in the health and wellness space.

Guillermo Rodriguez Navarrete, the founder and CEO of Nutrillermo, and Elaine Ladd, the chief pharmacy officer of Pharmacy Development Services (PDS), discuss challenges pharmacists may face while expanding into the health and wellness space.

Guillermo Rodriguez Navarrete, the founder and CEO of Nutrillermo, and Elaine Ladd, the chief pharmacy officer of Pharmacy Development Services (PDS), discuss the 2021 Virtual PDS Conference session on growth opportunities in the health and wellness space for pharmacy.

Simko discussed how to retain new patients to continue to bring in new opportunities and better results for pharmacies everywhere.

Pharmacy Times spoke with Lauren Simko, managing performance specialist at Pharmacy Development Services, about her presentation "Elevated Patients Experiences: Lengthen the Patient Lifecycle to Increase Revenue."

In addition to improving health care access for patients, point-of-care testing in pharmacies can drive customer demand and satisfaction.

Heart failure can involve multiple factors, but heart muscle scarring is thought to be an important contributing factor in up to two-thirds of patients with HFpEF.

Patient engagement programs should continually evolve in order to meet patient needs and behaviors.

With the creation of a diabetes prevention program, participants are able to make lasting behavioral changes, such as eating healthier, increasing physical activity, and improving problem-solving skills.

High engagement and collaboration between health systems and health plans is essential to implementing value-based models, according to a session at the Pharmacy Quality Alliance 2021 Annual Conference.

Policy changes impacting the star ratings for 2022 include additional flexibility provided during the COVID-19 pandemic and a revised Extreme and Uncontrollable Circumstances policy.